Developer docs
API playgroundTry for free, no card

Search company profiles

Abiogen Pharma

Full company profile

uuid0009uah

Namestring
Abiogen Pharma
Legal namestring
Abiogen Pharma S.p.A.
Websiteurl
abiogen.it
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Abiogen Pharma is an Italian pharmaceutical company founded in 1997 and headquartered in Pisa, with roots spanning five generations of the Di Martino family. The company is owned via MDM Holding S.p.A. and operates across six therapeutic areas: bone metabolism and musculoskeletal, hypovitaminosis D, pain and viscosupplementation, dermatology, respiratory, and diabetology. Its flagship technological differentiator is an internally developed portfolio of bisphosphonate molecules (Etidronate, Clodronate, Alendronate, Neridronate), with Neridronate holding first-in-class Italian approvals for rare diseases osteogenesis imperfecta and CRPS, plus FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations for U.S. development.

The commercial portfolio comprises branded pharmaceutical drugs (Dibase vitamin D, Nerixia/neridronate, Clasteon, Binosto effervescent alendronate, Acetamol analgesics, Januvia/Janumet via MSD licence), medical devices (Cingal, Jonexa Up cross-linked hyaluronic acid for viscosupplementation), food supplements (Calciobase, D3Base Junior), and Sarcobase — a patented L-leucine, Omega 3, and L. paracasei composition for muscle trophism. Manufacturing is fully vertically integrated at a 120,000 m2 Pisa site with GMP certification since 2005 (EU-GMP Annex 13), spanning oral solids (350-400 tons/yr), injectables (35M ampoules/yr), semi-solids, liquids, liquid-filled capsules, and sticks; the site also runs a CMO/CDMO business for third-party clients.

The business model is multi-stream: (1) branded pharma and supplement sales in Italy via a 150-strong Scientific Representative field force under D. Leg.vo 219/06 compliance; (2) international distribution through a licensing-out network of 20+ partners across 40+ countries; (3) direct subsidiary sales in Germany (Altamedics, acquired December 2022) and Switzerland (EffRx, 97.09% acquired May 2023); and (4) CMO/CDMO services. Reported 2024 revenue was EUR 168 million (Italian domestic EUR 141.7 million) with 460 employees as of 31 December 2024.

Short descriptiontext

Abiogen Pharma is an Italian pharmaceutical company founded in 1997 that develops, manufactures, and commercializes branded drugs, bisphosphonates, medical devices, and supplements across bone, pain, dermatology, respiratory, and diabetology therapeutic areas, serving Italian NHS and specialty physicians directly and 40+ countries via licensing partners and European subsidiaries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersPisa, Italy
HQ citystring
Pisa
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, bisphosphonate therapies, bone metabolism drugs, contract manufacturing services, viscosupplementation devices
Industry3 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Sale of branded pharmaceutical drugs, medical devices, food supplements, and foods for special medical purposes across six therapeutic areas (bone metabolism, hypovitaminosis D, pain/viscosupplementation, respiratory, dermatology, diabetology) through direct sales force in Italy and distributor/partner networks internationally. Revenue reported at EUR 168 million in 2024, with Italian domestic turnover of EUR 141,706,708 in 2024.

abiogen.it
2Contract Manufacturing (CMO/CDMO)
TypeProfessional Services
Description

Contract development and manufacturing services for external pharmaceutical clients offering formulation development, analytical testing, scale-up, and commercial production. Services span from early clinical phases through commercial scale across multiple dosage forms.

abiogen.it
3Licensing Out
TypeLicensing Royalties
Description

Licensing out proprietary products and molecules to international pharmaceutical partners for commercialization in their respective territories. More than 20 partners across over 40 countries. Products include Acetamol, Codamol, Clasteon, Dibase, Gliconorm, Sursum, and food supplements.

abiogen.it
4Licensing In
TypeLicensing Royalties
Description

Licensing in products from international pharmaceutical partners for commercialization in Italy. Partners include Anika Therapeutics (hyaluronic acid/Cingal), Om Pharma (Broncho Munal), Mabxience, ImasMed (Jonexa Up), Hisamitsu Pharmaceutical (Ketoprofene/Keplat), MSD (Januvia/Janumet), Organon Italia (Alendronato/Alendros), Galenica AB, Synthon B.V., and Bened Biomedical LTD.

abiogen.it
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure
Pricing details1 tier
1Pharmaceutical drugs, medical devices, food supplements, and foods for special medical purposes
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing for prescription pharmaceutical products is not publicly disclosed. Food supplement products have retail pricing (e.g., Calciobase EUR 15.80 for 30 sticks). Contract manufacturing services are quoted per project based on complexity and scope.

abiogen.it
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Abiogen Pharma is an Italian pharmaceutical company that develops, manufactures, and commercializes prescription drugs (notably bisphosphonates such as neridronate, clodronate, alendronate, and etidronate), vitamin D products, analgesics, and treatments for diabetes, dermatology, and respiratory conditions. In addition to its proprietary drug portfolio, the company sells medical devices for viscosupplementation, food supplements and foods for special medical purposes, and offers contract manufacturing and development (CMO/CDMO) services to third-party pharmaceutical clients across multiple dosage forms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Revenue of EUR 168 million in 2024
+3 more records
Product overview1 text field

Abiogen Pharma is an Italian pharmaceutical company founded in 1997, operating in bone metabolism, musculoskeletal, pain management, and related therapeutic areas. The company offers a diversified portfolio comprising: (1) Pharmaceutical drugs including bisphosphonates (NERIXIA/neridronate, CLASTEON/clodronate, BINOSTO/alendronate, ALENDROS), vitamin D products (DIBASE, DIBASELAB), analgesics (ACETAMOL/paracetamol, CODAMOL), and treatments for diabetes, dermatology, and respiratory conditions; (2) Medical devices including viscosupplementation products (CINGAL, JONEXA UP) with cross-linked hyaluronic acid; (3) Food supplements including calcium citrate (CALCIOBASE) and vitamin D3 (D3BASE JUNIOR) for bone health; (4) Foods for special medical purposes (SARCOBASE) for muscle support; and (5) Contract manufacturing services (CMO/CDMO). The company operates through domestic Italian sales organization, international licensing partnerships covering 40+ countries, and direct presence via subsidiaries (EffRx Pharmaceuticals, Altamedics).

Product and service11 records
1ACETAMOL
CategoryPharmaceutical drug
Description

Paracetamol-based analgesic for pain and fever relief, available in multiple formulations including tablets, suppositories, syrup, and effervescent tablets for adults and children.

2ALENDROS
CategoryPharmaceutical drug
Description

Alendronate tablet for the treatment of osteoporosis, belonging to the bisphosphonate class; licensed in from Organon Italia for the Italian market.

3BINOSTO
CategoryPharmaceutical drug
Description

Effervescent sodium alendronate tablet for treatment of postmenopausal osteoporosis; flagship product acquired from EffRx Pharmaceuticals.

4DIBASE
CategoryPharmaceutical drug
Description

Cholecalciferol (vitamin D3) product for prevention and treatment of vitamin D deficiency, available in multiple dosages from 2,000 to 300,000 IU.

5NERIXIA
CategoryPharmaceutical drug
Description

Sodium neridronate injection for metabolic osteopathies; the first drug to obtain Italian regulatory approval for rare diseases such as osteogenesis imperfecta and algodystrophy (CRPS).

6CINGAL
CategoryMedical device
Description

Cross-linked hyaluronic acid with ancillary triamcinolone hexacetonide medical device supplied in 5ml glass syringe for viscosupplementation in osteoarthritis; licensed in from Anika Therapeutics.

7JONEXA UP
CategoryMedical device
Description

Cross-linked hyaluronic acid medical device for intra-articular injection in osteoarthritis treatment; licensed in from ImasMed.

8CALCIOBASE
CategoryFood supplement
Description

Calcium citrate supplement in stick format for bone health, gluten/lactose/sugar free.

9D3BASE JUNIOR
CategoryFood supplement
Description

Vitamin D3 supplement in gumdrop form for children above 4 years, available in Orange and Wild Berries flavors, 600 IU per serving.

10SARCOBASE
CategoryFood for special medical purposes
Description

Food for special medical purposes with L-leucine, Omega 3 and Lactobacillus paracasei patented composition for muscle trophism support.

11Contract Manufacturing (CMO/CDMO)
CategoryService
Description

Contract development and manufacturing services for third-party pharmaceutical clients offering formulation development, analytical testing, scale-up, and commercial production across orals, injectables, semisolids, oral liquids, liquid-filled capsules, and sticks.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Abiogen Pharma licensed neridronate to Ambros Therapeutics for development and commercialization outside Italy. Ambros Therapeutics launched in December 2025 with $125 million Series A funding to conduct Phase 3 CRPS-RISE trial of neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1) in the United States. Neridronate has already received FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations. First patient dosed June 2026.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights9 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Abiogen Pharma

Specialty Pharmaceuticalsabiogen.it

Abiogen Pharma is an Italian pharmaceutical company founded in 1997 that develops, manufactures, and commercializes branded drugs, bisphosphonates, medical devices, and supplements across bone, pain, dermatology, respiratory, and diabetology therapeutic areas, serving Italian NHS and specialty physicians directly and 40+ countries via licensing partners and European subsidiaries.

What Abiogen Pharma does

Abiogen Pharma is an Italian pharmaceutical company founded in 1997 and headquartered in Pisa, with roots spanning five generations of the Di Martino family. The company is owned via MDM Holding S.p.A. and operates across six therapeutic areas: bone metabolism and musculoskeletal, hypovitaminosis D, pain and viscosupplementation, dermatology, respiratory, and diabetology. Its flagship technological differentiator is an internally developed portfolio of bisphosphonate molecules (Etidronate, Clodronate, Alendronate, Neridronate), with Neridronate holding first-in-class Italian approvals for rare diseases osteogenesis imperfecta and CRPS, plus FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations for U.S. development.

The commercial portfolio comprises branded pharmaceutical drugs (Dibase vitamin D, Nerixia/neridronate, Clasteon, Binosto effervescent alendronate, Acetamol analgesics, Januvia/Janumet via MSD licence), medical devices (Cingal, Jonexa Up cross-linked hyaluronic acid for viscosupplementation), food supplements (Calciobase, D3Base Junior), and Sarcobase — a patented L-leucine, Omega 3, and L. paracasei composition for muscle trophism. Manufacturing is fully vertically integrated at a 120,000 m2 Pisa site with GMP certification since 2005 (EU-GMP Annex 13), spanning oral solids (350-400 tons/yr), injectables (35M ampoules/yr), semi-solids, liquids, liquid-filled capsules, and sticks; the site also runs a CMO/CDMO business for third-party clients.

The business model is multi-stream: (1) branded pharma and supplement sales in Italy via a 150-strong Scientific Representative field force under D. Leg.vo 219/06 compliance; (2) international distribution through a licensing-out network of 20+ partners across 40+ countries; (3) direct subsidiary sales in Germany (Altamedics, acquired December 2022) and Switzerland (EffRx, 97.09% acquired May 2023); and (4) CMO/CDMO services. Reported 2024 revenue was EUR 168 million (Italian domestic EUR 141.7 million) with 460 employees as of 31 December 2024.

Abiogen Pharma firmographics

Firmographics
Name
Abiogen Pharma
Legal name
Abiogen Pharma S.p.A.
Website
https://abiogen.it
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
251–500 employees
Short description
Abiogen Pharma is an Italian pharmaceutical company founded in 1997 that develops, manufactures, and commercializes branded drugs, bisphosphonates, medical devices, and supplements across bone, pain, dermatology, respiratory, and diabetology therapeutic areas, serving Italian NHS and specialty physicians directly and 40+ countries via licensing partners and European subsidiaries.
Ownership category
akta.pro rank

Abiogen Pharma industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Pharmaceutical manufacturing
  • Bisphosphonate therapies
  • Bone metabolism drugs
  • Contract manufacturing services
  • Viscosupplementation devices

Where Abiogen Pharma is headquartered

Location

Headquarters

HQ city
Pisa
HQ country
Italy
HQ region
Europe

Offices3 records

Markets served

Abiogen Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Sale of branded pharmaceutical drugs, medical devices, food supplements, and foods for special medical purposes across six therapeutic areas (bone metabolism, hypovitaminosis D, pain/viscosupplementation, respiratory, dermatology, diabetology) through direct sales force in Italy and distributor/partner networks internationally. Revenue reported at EUR 168 million in 2024, with Italian domestic turnover of EUR 141,706,708 in 2024.
  2. Contract Manufacturing (CMO/CDMO): Contract development and manufacturing services for external pharmaceutical clients offering formulation development, analytical testing, scale-up, and commercial production. Services span from early clinical phases through commercial scale across multiple dosage forms.
  3. Licensing Out: Licensing out proprietary products and molecules to international pharmaceutical partners for commercialization in their respective territories. More than 20 partners across over 40 countries. Products include Acetamol, Codamol, Clasteon, Dibase, Gliconorm, Sursum, and food supplements.
  4. Licensing In: Licensing in products from international pharmaceutical partners for commercialization in Italy. Partners include Anika Therapeutics (hyaluronic acid/Cingal), Om Pharma (Broncho Munal), Mabxience, ImasMed (Jonexa Up), Hisamitsu Pharmaceutical (Ketoprofene/Keplat), MSD (Januvia/Janumet), Organon Italia (Alendronato/Alendros), Galenica AB, Synthon B.V., and Bened Biomedical LTD.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPharmaceutical drugs, medical devices, food supplements, and foods for special medical purposes

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Abiogen Pharma product offering

Product offering

Core offering

Abiogen Pharma is an Italian pharmaceutical company that develops, manufactures, and commercializes prescription drugs (notably bisphosphonates such as neridronate, clodronate, alendronate, and etidronate), vitamin D products, analgesics, and treatments for diabetes, dermatology, and respiratory conditions. In addition to its proprietary drug portfolio, the company sells medical devices for viscosupplementation, food supplements and foods for special medical purposes, and offers contract manufacturing and development (CMO/CDMO) services to third-party pharmaceutical clients across multiple dosage forms.

Product overview

Abiogen Pharma is an Italian pharmaceutical company founded in 1997, operating in bone metabolism, musculoskeletal, pain management, and related therapeutic areas. The company offers a diversified portfolio comprising: (1) Pharmaceutical drugs including bisphosphonates (NERIXIA/neridronate, CLASTEON/clodronate, BINOSTO/alendronate, ALENDROS), vitamin D products (DIBASE, DIBASELAB), analgesics (ACETAMOL/paracetamol, CODAMOL), and treatments for diabetes, dermatology, and respiratory conditions; (2) Medical devices including viscosupplementation products (CINGAL, JONEXA UP) with cross-linked hyaluronic acid; (3) Food supplements including calcium citrate (CALCIOBASE) and vitamin D3 (D3BASE JUNIOR) for bone health; (4) Foods for special medical purposes (SARCOBASE) for muscle support; and (5) Contract manufacturing services (CMO/CDMO). The company operates through domestic Italian sales organization, international licensing partnerships covering 40+ countries, and direct presence via subsidiaries (EffRx Pharmaceuticals, Altamedics).

Differentiator

Problem solved

Functional benefit

Products and services

  • ACETAMOL Paracetamol-based analgesic for pain and fever relief, available in multiple formulations including tablets, suppositories, syrup, and effervescent tablets for adults and children.
  • ALENDROS Alendronate tablet for the treatment of osteoporosis, belonging to the bisphosphonate class; licensed in from Organon Italia for the Italian market.
  • BINOSTO Effervescent sodium alendronate tablet for treatment of postmenopausal osteoporosis; flagship product acquired from EffRx Pharmaceuticals.
  • DIBASE Cholecalciferol (vitamin D3) product for prevention and treatment of vitamin D deficiency, available in multiple dosages from 2,000 to 300,000 IU.
  • NERIXIA Sodium neridronate injection for metabolic osteopathies; the first drug to obtain Italian regulatory approval for rare diseases such as osteogenesis imperfecta and algodystrophy (CRPS).
  • CINGAL Cross-linked hyaluronic acid with ancillary triamcinolone hexacetonide medical device supplied in 5ml glass syringe for viscosupplementation in osteoarthritis; licensed in from Anika Therapeutics.
  • JONEXA UP Cross-linked hyaluronic acid medical device for intra-articular injection in osteoarthritis treatment; licensed in from ImasMed.
  • CALCIOBASE Calcium citrate supplement in stick format for bone health, gluten/lactose/sugar free.
  • D3BASE JUNIOR Vitamin D3 supplement in gumdrop form for children above 4 years, available in Orange and Wild Berries flavors, 600 IU per serving.
  • SARCOBASE Food for special medical purposes with L-leucine, Omega 3 and Lactobacillus paracasei patented composition for muscle trophism support.
  • Contract Manufacturing (CMO/CDMO) Contract development and manufacturing services for third-party pharmaceutical clients offering formulation development, analytical testing, scale-up, and commercial production across orals, injectables, semisolids, oral liquids, liquid-filled capsules, and sticks.

Quantifiable outcome

  • Revenue of EUR 168 million in 2024
  • +3 more outcomes

Companies that use Abiogen Pharma

Customer profile

Named customers1 record

Segments6 records

Ideal customer profiles3 records

Abiogen Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Abiogen Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Ambros TherapeuticscoreStrategic or Co-development PartnerAbiogen Pharma licensed neridronate to Ambros Therapeutics for development and commercialization outside Italy. Ambros Therapeutics launched in December 2025 with $125 million Series A funding to conduct Phase 3 CRPS-RISE trial of neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1) in the United States. Neridronate has already received FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations. First patient dosed June 2026.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Abiogen Pharma competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights9 records

Customer concentration

Abiogen Pharma social profiles

Digital presence

Abiogen Pharma compliance and trust

Trust signal

Compliance9 records

Abiogen Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Abiogen Pharma leadership team

Management profile

Number of profiles

Profiles4 records

Abiogen Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Abiogen Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Abiogen Pharma M&A and investment

M&A and investment

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abiogen Pharma

What does Abiogen Pharma do?

Abiogen Pharma is an Italian pharmaceutical company that develops, manufactures, and commercializes prescription drugs (notably bisphosphonates such as neridronate, clodronate, alendronate, and etidronate), vitamin D products, analgesics, and treatments for diabetes, dermatology, and respiratory conditions. In addition to its proprietary drug portfolio, the company sells medical devices for viscosupplementation, food supplements and foods for special medical purposes, and offers contract manufacturing and development (CMO/CDMO) services to third-party pharmaceutical clients across multiple dosage forms.

Is Abiogen Pharma a public or private company?

Abiogen Pharma is a private company. It is classified as family owned and is currently operating.

When was Abiogen Pharma founded?

Abiogen Pharma was founded in 1997. It employs 251 to 500 people.

Where is Abiogen Pharma based?

Abiogen Pharma is headquartered in Pisa, Italy, in the Europe region.

How does Abiogen Pharma make money?

Four revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are contract Manufacturing (CMO/CDMO), licensing Out and licensing In.

Does Abiogen Pharma have an API?

No public API is recorded for Abiogen Pharma.

What industry is Abiogen Pharma in?

Abiogen Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceAmbros Launches With $125M To Bring Italian Non-Opioid Pain Drug to AmericaAmbros Therapeutic launched Tuesday with a $125 million Series A raise to advance neridronate, a non-opioid pain medicine already approved in Italy, into Phase III trials for complex regional pain syndrome type 1 (CRPS-1) in the United States. The funding was backed by RA Capital Management and Patient Square Capital's Enavate Sciences platform, with the therapy receiving three FDA designations—breakthrough therapy, fast track, and orphan drug—to accelerate development. Ambros licensed neridronate from Italy's Abiogen Pharma, which developed the bisphosphonate-class drug for pain management and bone-related conditions.AmbrostherapeuticsAMBROSAmbros Therapeutics launched on December 16, 2025, as a clinical-stage biotechnology company backed by a $125 million Series A financing co-led by RA Capital Management and Patient Square Capital's Enavate Sciences, with participation from Abiogen Pharma and other life sciences investors. The funding will support a pivotal Phase 3 clinical trial for neridronate (CRPS-RISE) in Complex Regional Pain Syndrome Type 1, for which the FDA has granted Breakthrough Therapy, Fast-Track, and Orphan Drug designations, with enrollment targeted to begin in Q1 2026. Ambros licensed exclusive North American rights to neridronate from Italian pharmaceutical company Abiogen Pharma, which has already treated over 600,000 patients with the drug in Italy for CRPS and other indications.PR NewswireABIOGEN PHARMA COMPLETES THE ACQUISITION OF EFFRXAbiogen Pharma S.p.A. has completed the acquisition of a 97.09% stake in Swiss pharmaceutical company EffRx Pharmaceuticals SA, a developer and marketer of prescription drugs targeting musculoskeletal and rare pathologies. The key product of EffRx is buffered soluble alendronate, a bisphosphonate for osteoporosis treatment that Abiogen has already distributed in Italy since 2014 under a license agreement. This deal follows Abiogen's acquisition of the German company Altamedics in late 2022 and represents a further step in the company's internationalization strategy that began in 2015.PR NewswireABIOGEN PHARMA FINALISE L'ACQUISITION D'EFFRXAbiogen Pharma S.p.A., an Italian pharmaceutical company based in Pisa, has completed the acquisition of a 97.09% stake in EffRx Pharmaceuticals SA, a Swiss company based in Freienbach that develops and commercializes medications for musculoskeletal and rare diseases. The acquired company's key product is buffered soluble alendronate, a bisphosphonate drug for osteoporosis treatment that Abiogen has already been distributing in Italy since 2014 under a licensing agreement. This transaction, following Abiogen's acquisition of German company Altamedics in late 2022, represents a significant step in Abiogen's internationalization strategy that began in 2015.PR NewswireAbiogen Pharma finaliza la adquisición de EffRxItalian pharmaceutical company Abiogen Pharma S.p.A. completed the acquisition of a 97.09% stake in Swiss company EffRx Pharmaceuticals SA on May 29, 2023, strengthening its international presence. EffRx develops and commercializes medications for musculoskeletal and rare diseases, including buffered soluble alendronate for osteoporosis, which Abiogen has distributed in Italy since 2014 under a licensing agreement. The deal follows Abiogen's acquisition of German company Altamedics in late 2022 and represents the next step in its internationalization strategy launched in 2015.PR NewswireABIOGEN PHARMA SCHLIESST DIE ÜBERNAHME VON EFFRX ABAbiogen Pharma S.p.A. has completed the acquisition of a 97.09% stake in Swiss company EffRx Pharmaceuticals SA, announced on May 29, 2023. EffRx develops and markets prescription medicines targeting musculoskeletal disorders and rare diseases, with its lead product being buffered soluble alendronate, a bisphosphonate for osteoporosis treatment that Abiogen has already been distributing in Italy since 2014 under a licensing agreement. The acquisition, following Abiogen's purchase of German company Altamedics in late 2022, marks a significant step in Abiogen's internationalization strategy that began in 2015, positioning the Italian pharmaceutical firm for broader expansion into European and international markets.FinSMEsAbiogen Pharma Acquires 97,09% Stake in EffRx PharmaceuticalsAbiogen Pharma acquired a 97.09% stake in EffRx Pharmaceuticals, strengthening its internationalization strategy which began in 2015. The deal details have not been disclosed, but this acquisition allows Abiogen to enhance its portfolio in the treatment of musculoskeletal and rare diseases with EffRx's key product, buffered soluble alendronate.Fortune ItaliaAbiogen Pharma acquisisce EffRx (e l’alendronato)Abiogen Pharma Spa has acquired 97.09% of the Swiss company EffRx Pharmaceuticals SA, which is significant due to the strategic relevance of EffRx's main molecule, effervescent alendronate, already licensed to Abiogen for distribution in Italy since 2014. This acquisition aligns with Abiogen's international expansion strategy initiated in 2015 and emphasizes their commitment to bone health and rare diseases. The deal aims to strengthen Abiogen's position in Italy and facilitate further international growth.